Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (251-260 of 466) with videos related to

Pageof 47
Sort By:
Oncoimmunology|July 30, 2016
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaNatali Pflug, Sandra Kluth, Jörg J Vehreschild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysisJohannes Schetelig, Anja van Biezen, Ronald Brand, et al.
Leukemia|May 16, 2024
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 updateJitka Malcikova, Sarka Pavlova, Panagiotis Baliakas, et al.
British Journal of Haematology|March 13, 2018
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trialJohannes Schetelig, Cornelia S Link, Gernot Stuhler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupStephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Michael Hallek, William Wierda, et al.
Acta Neuropathologica Communications|August 24, 2016
Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse modelAnnika Scheffold, Inge R Holtman, Sandra Dieni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly TrialEva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trialSebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.
Pageof 47

Showing results (251-260 of 466) with videos related to

Sort By:
Pageof 47
Oncoimmunology|July 30, 2016
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaNatali Pflug, Sandra Kluth, Jörg J Vehreschild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysisJohannes Schetelig, Anja van Biezen, Ronald Brand, et al.
Leukemia|May 16, 2024
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 updateJitka Malcikova, Sarka Pavlova, Panagiotis Baliakas, et al.
British Journal of Haematology|March 13, 2018
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trialJohannes Schetelig, Cornelia S Link, Gernot Stuhler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupStephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Michael Hallek, William Wierda, et al.
Acta Neuropathologica Communications|August 24, 2016
Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse modelAnnika Scheffold, Inge R Holtman, Sandra Dieni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly TrialEva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trialSebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.
Pageof 47